Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA agrees to review Roche’s Tecentriq combination for breast cancer

pharmaceutical-technologyDecember 18, 2018

Tag: FDA , Roche , Breast Cancer , Tecentriq

PharmaSources Customer Service